nach oben

International Urology and Nephrology

Erschienen in:

01.03.2009 | Nephrology - Original Paper

Serum fibroblast growth factor-23 levels in chronic haemodialysis patients

verfasst von: Salwa Ibrahim, Laila Rashed

Erschienen in: International Urology and Nephrology | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Fibroblast growth factor-23 (FGF23) is a circulating factor that regulates renal reabsorption of inorganic phosphate. Serum FGF23 level is increased in chronic kidney disease (CKD) patients as a compensatory mechanism to hyperphosphataemia. FGF23 directly signals in the parathyroid glands and can be used to predict future secondary hyperparathyroidism in dialysis patients. We examined the relationship between FGF23 and serum calcium, phosphate, 1,25(OH)₂D₃, and PTH levels in haemodialysis patients.

Methods

FGF23 and the above mentioned characteristics were measured in 50 chronic haemodialysis patients. We analysed the correlation between FGF23 and the other characteristics by using the Pearson correlation coefficient and multiple regression analysis.

Results

FGF23 was significantly increased in haemodialysis patients compared with healthy controls (1525 ± 373 vs. 37 ± 9 pg/ml, P < 0.0001). There was a significant negative correlation between log FGF23 and 1,25(OH)₂D₃ (R = −0.375, P = 0.009) and a significant positive correlation between log FGF23 and log PTH values (R = 0.287, P = 0.041). In multiple regression analysis log PTH and 1,25(OH)₂D₃ values were independent predictors of log FGF23 (P = 0.037 and 0.009, respectively).

Conclusions

Our results revealed a marked increase in FGF23 levels in haemodialysis patients. PTH and vitamin D3 were independent predictors of FGF23 in the study group. Serum phosphate did not correlate with or predict FGF23 level despite the high prevalence of hyperphosphataemia in the study group.

Itoh N, Ornitz DM (2004) Evolution of FGF and FGF gene families. Trends Genet 20:563–569. doi:10.1016/j.tig.2004.08.007 PubMedCrossRef

Shimada T, Mizutani S, Muto T et al (2001) Cloning and characterization of FGF23 as a causative factor of tumor induced osteomalacia. Proc Natl Acad Sci USA 98:6500–6505. doi:10.1073/pnas.101545198 PubMedCrossRef

Yamashita T, Yoshioka M, Itoh N (2000) Identification of a novel fibroblast growth factor, FGF23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277:494–498. doi:10.1006/bbrc.2000.3696 PubMedCrossRef

Liu S, Guo R, Simpson LG et al (2003) Regulation of fibroblast growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419–37426. doi:10.1074/jbc.M304544200 PubMedCrossRef

Liu S, Zhou J, Tang W et al (2006) Pathogenic role of FGF23 in Hyp mice. Am J Physiol Endocrinol Metab 291:E38–E49. doi:10.1152/ajpendo.00008.2006 PubMedCrossRef

Liu S, Quarles D (2007) How fibroblast growth factor 23 works. J Am Soc Nephrol 18:1637–1647. doi:10.1681/ASN.2007010068 PubMedCrossRef

Ornitz DM (2000) FGFs, heparan sulphate and FGFRs: complex interactions essential for development. Bioessays 22:108–112. doi :10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-MPubMedCrossRef

Urakawa I, Yamazaki Y, Shimada T et al (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770–774. doi:10.1038/nature05315 PubMedCrossRef

Shimada T, Kakitani M, Yamazaki Y et al (2004) Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561–568PubMed

10.

Kuro-o M, Matsumura Y, Aizawa H et al (1997) Mutation of the mouse Klotho gene leads to a syndrome resembling aging. Nature 390:45–51. doi:10.1038/36285 PubMedCrossRef

11.

Liu S, Tang W, Zhou J et al (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17:1305–1315. doi:10.1681/ASN.2005111185 PubMedCrossRef

12.

Peters BS, Moyses RM, Jorgetti V et al (2007) Effects of Parathyroidectomy on bone remodelling markers and vitamin D status in patients with chronic kidney disease-mineral and bone disorder. Int Urol Nephrol 39(4):1251–1256. doi:10.1007/s11255-007-9254-2 PubMedCrossRef

13.

Saito H, Maeda A, Ohtomo S et al (2005) Circulating FGF23 is regulated by 1 alpha, 25 dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280:2543–2549. doi:10.1074/jbc.M408903200 PubMedCrossRef

14.

Yamazaki Y, Okazaki R, Shibata M et al (2002) Increased circulatory level of biologically active full length FGF23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957–4960. doi:10.1210/jc.2002-021105 PubMedCrossRef

15.

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification (2002) Am J Kidney Dis 39: S1–S266

16.

Larsson T, Nisbeth U, Ljunggren O et al (2003) Circulating concentration of FGF23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64:2272–2279. doi:10.1046/j.1523-1755.2003.00328.x PubMedCrossRef

17.

Westerberg P, Linde T, Wikstrom B et al (2007) Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant 22:3202–3207. doi:10.1093/ndt/gfm347 PubMedCrossRef

18.

Shigematsu T, Kazama JJ, Yamashita T et al (2004) Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44:250–256. doi:10.1053/j.ajkd.2004.04.029 PubMedCrossRef

19.

Imanishi Y, Inaba M, Nakatsuka K et al (2004) FGF23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65(5):1943–1946. doi:10.1111/j.1523-1755.2004.00604.x PubMedCrossRef

20.

Okada N, Hayashi D, Tomida K et al (2004) Role of FGF23 in secondary hyperparathyroidism in patients with mild chronic kidney disease. J Am Soc Nephrol 15:282A. doi:10.1097/01.ASN.0000136132.20189.95 CrossRef

21.

Schiavi SC (2006) Fibroblast growth factor 23: the making of a hormone. Kidney Int 69:425–427. doi:10.1038/sj.ki.5000168 PubMedCrossRef

22.

Perward F, Azam N, Zhang MYH et al (2004) Dietary phosphorus regulates serum FGF23 concentrations and 1,25 (OH)₂D metabolism in mice. J Bone Miner Res 19:S251

23.

Gupta A, Winer K, Econs MJ et al (2004) FGF23 is elevated by chronic hyperphosphataemia. J Clin Endocrinol Metab 89:4489–4492. doi:10.1210/jc.2004-0724 PubMedCrossRef

24.

Urena-Torres P, Friedlander G, de Vernejoul MC et al (2008) Bone mass does not correlate with the serum fibroblast growth factor 23 in haemodialysis patients. Kidney Int 73:102–107. doi:10.1038/sj.ki.5002622 PubMedCrossRef

25.

Jonsson K (2005) The role of fibroblast growth factor 23 in renal disease. Nephrol Dial Transplant 20:479–482. doi:10.1093/ndt/gfh701 PubMedCrossRef

26.

Nakanishi S, Kazama JJ, Nii-Kono T et al (2005) Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 67:1171–1178. doi:10.1111/j.1523-1755.2005.00184.x PubMedCrossRef

27.

Kazama JJ, Sato F, Omori K et al (2004) Pre-treatment serum FGF23 levels predict the efficacy of calcitriol therapy in dialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 15:282A

28.

Wei M, Taskapan H, Esbaei K et al (2006) K/DOQI guidelines requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them? Int Urol Nephrol 38(2):739–743. doi:10.1007/s11255-006-0082-6 PubMedCrossRef

29.

Locatelli F, Pisoni RL, Combe C et al (2004) Anemia in hemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19:121–132. doi:10.1093/ndt/gfg458 PubMedCrossRef

30.

Taskapan H, Wei M, Oreopoulos DG (2006) 25 (OH) vitamin D3 in patients with chronic kidney disease and those on dialysis: rediscovering its importance. Int Urol Nephrol 38(2):317–322. doi:10.1007/s11255-006-0081-7 CrossRef

Titel: Serum fibroblast growth factor-23 levels in chronic haemodialysis patients
verfasst von: Salwa Ibrahim
Laila Rashed
Publikationsdatum: 01.03.2009
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 1/2009
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-008-9466-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2009

The significance of microscopic bladder neck invasion in radical prostatectomies: pT4 disease?

Accuracy of retinal changes in predicting microalbuminuria among elderly hypertensive patients: a cross-sectional study from a teaching hospital in South India

Hematospermia: etiological and management considerations

The protective effect of erythropoietin infusion on testicular torsion/detorsion: an experimental study

Are children with congenital solitary kidney at risk for lifelong complications? A lack of prediction demands caution